LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial.

    Langley, Joanne M / Halperin, Scott A / Rubin, Earl / White, Craig / McNeil, Shelly / Mutch, Jill / Mackinnon-Cameron, Donna / Smith, Bruce

    The Pediatric infectious disease journal

    2012  Volume 31, Issue 2, Page(s) 189–192

    Abstract: Background: Two pentavalent infant vaccines that contain either 5 or 3 component acellular pertussis antigens are authorized in Canada. Because of changes in vaccine use by provinces over time and movement of families across jurisdictions, it is ... ...

    Abstract Background: Two pentavalent infant vaccines that contain either 5 or 3 component acellular pertussis antigens are authorized in Canada. Because of changes in vaccine use by provinces over time and movement of families across jurisdictions, it is possible that children are exposed to different combination vaccines during the primary infant immunization schedule. The safety and immunogenicity of mixed primary infant schedules is unknown.
    Methods: In a double-blind multicenter trial, 2-month-old healthy infants were randomized to 1 of 2 schedules at 2, 4, and 6 months of age (either Pediacel, Pediacel, Infanrix [PPI] or Infanrix, Pediacel, Pediacel [IPP]). Solicited local and systemic adverse events (AEs) were collected by parent diary on days 0 through 7; unsolicited AEs were collected for 31 days after each dose. Immune responses to polypolyribosylribitol phosphate capsular polysaccharide (PRP) (Haemophilus influenzae type b) and pertussis antigens were assessed before the first dose and 28 days after the 6 month (third) dose.
    Results: In all, 127 infants were randomized to IPP and 126 to PPI. The percentage of children with anti-PRP responses ≥0.15 μg/mL after dose 3 was higher in the IPP than in the PPI group (98.3, 95% CI: 94.1, 99.8 vs. 86.1%, 95% CI: 78.6, 91.7, P < 0.001). Antipertussis toxin and anti-fimbriae 2 and 3 responses were statistically significantly higher in the IPP than in the PPI group. Higher filamentous hemagglutinin responses occurred in PPI than in IPP. No difference between groups was observed in pertactin responses.Systemic AEs were similar between the 2 vaccine schedules. Irritability (67.2 vs. 51.6, P = 0.014) and mild crying (35.2% vs. 23.0%, P = 0.037) were more common after the 6-month dose in the PPI compared with the IPP group, as were overall systemic reactions (any intensity) for the PPI group after this dose (80.0 vs. 68.0, P = 0.042).
    Conclusion: Mixed 2-, 4-, 6-month pentavalent infant vaccine schedules had different immunogenicity and reactogenicity, with a PPI schedule being more reactogenic, and less immunogenic for PRP and fimbriae 2 and 3 antigens at 7 months. It is preferable to complete the primary infant 3-dose vaccine series with the same vaccine, rather than considering infant vaccines as interchangeable.
    MeSH term(s) Antibodies, Bacterial/blood ; Canada ; Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage ; Diphtheria-Tetanus-Pertussis Vaccine/adverse effects ; Diphtheria-Tetanus-Pertussis Vaccine/immunology ; Double-Blind Method ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Haemophilus Vaccines/administration & dosage ; Haemophilus Vaccines/adverse effects ; Haemophilus Vaccines/immunology ; Humans ; Immunization Schedule ; Incidence ; Infant ; Infant, Newborn ; Male ; Poliovirus Vaccine, Inactivated/administration & dosage ; Poliovirus Vaccine, Inactivated/adverse effects ; Poliovirus Vaccine, Inactivated/immunology ; Vaccines, Conjugate/administration & dosage ; Vaccines, Conjugate/adverse effects ; Vaccines, Conjugate/immunology
    Chemical Substances Antibodies, Bacterial ; Diphtheria-Tetanus-Pertussis Vaccine ; Haemophilus Vaccines ; Poliovirus Vaccine, Inactivated ; Vaccines, Conjugate ; diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine
    Language English
    Publishing date 2012-02
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 392481-6
    ISSN 1532-0987 ; 0891-3668
    ISSN (online) 1532-0987
    ISSN 0891-3668
    DOI 10.1097/INF.0b013e318242462a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1852: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Hepatitis A and travel amongst Nova Scotia postsecondary students: evidence for a targeted vs. universal immunization strategy.

    Matheson, Katherine / Halperin, Beth / McNeil, Shelly / Langley, Joanne M / Mackinnon-Cameron, Donna / Halperin, Scott A

    Vaccine

    2010  Volume 28, Issue 51, Page(s) 8105–8111

    Abstract: Background: Canadian guidelines recommend hepatitis A virus (HAV) vaccination for high-risk persons, such as travelers to HAV-endemic areas. The US CDC advocates universal immunization.: Objectives: To explore whether a universal strategy for HAV ... ...

    Abstract Background: Canadian guidelines recommend hepatitis A virus (HAV) vaccination for high-risk persons, such as travelers to HAV-endemic areas. The US CDC advocates universal immunization.
    Objectives: To explore whether a universal strategy for HAV immunization rather than the Canadian targeted approach for travelers is justified by measuring compliance of postsecondary students with Canadian guidelines.
    Methods: A cross-sectional study using an electronic survey method elicited HAV risk factors, immunization history, disease status, and factors affecting immunization status from postsecondary students. Seropositivity was determined by measuring HAV antibodies in saliva from a convenience sample of survey participants within each study group. Statistical analysis used Fisher's exact test and logistic regression.
    Results: We received 2279 completed surveys (10.6% response) and 235 saliva samples (58.7% response). A total of 1380 (60.6%) participants had traveled to HAV-endemic regions and 1851 (81.2%) were planning to do so within the next 5 years. Less than half who traveled to HAV-endemic areas reported a history of HAV vaccination (48.0%). HAV seropositivity rates were higher amongst those who traveled to (63.6%) or were planning to travel to (55.0%) HAV-endemic areas than those who had never traveled or had no plans to travel to such areas (17.4%). Only 8.9% of unvaccinated students were seropositive (5.3% of Canadian-born students). Amongst unvaccinated, seropositive students, there was a nonsignificant trend for higher seropositivity in those who had previously traveled to HAV-endemic areas (14.7%) than those who had not traveled abroad (4.4%), suggesting an exposure to HAV during travel. Nearly all (96.5%) unvaccinated students, who were willing to be vaccinated based on current knowledge or if their doctor recommended it, indicated a willingness to receive vaccine if it were provided free of charge.
    Conclusions: Current Canadian guidelines for HAV vaccination are not being followed within the postsecondary student population. Given high rates of travel to HAV-endemic areas in this population, a universal approach to HAV vaccination may be warranted.
    MeSH term(s) Adult ; Animals ; Cross-Sectional Studies ; Female ; Guideline Adherence/statistics & numerical data ; Hepatitis A/epidemiology ; Hepatitis A/prevention & control ; Hepatitis A Antibodies/analysis ; Hepatitis A Vaccines/administration & dosage ; Hepatitis A Vaccines/immunology ; Humans ; Male ; Nova Scotia/epidemiology ; Saliva/immunology ; Students ; Travel ; Vaccination/methods ; Young Adult
    Chemical Substances Hepatitis A Antibodies ; Hepatitis A Vaccines
    Language English
    Publishing date 2010-11-29
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2010.09.107
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1930: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 458: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.

    Halperin, Scott A / Ward, Brian J / Dionne, Marc / Langley, Joanne M / McNeil, Shelly A / Smith, Bruce / Mackinnon-Cameron, Donna / Heyward, William L / Martin, J Tyler

    Human vaccines & immunotherapeutics

    2013  Volume 9, Issue 7, Page(s) 1438–1444

    Abstract: An additional one to three doses of hepatitis B vaccine are recommended for nonresponders to an initial standard three-dose series. We compared the safety and immunogenicity of an investigational hepatitis B surface antigen vaccine (HBsAg-1018) with a ... ...

    Abstract An additional one to three doses of hepatitis B vaccine are recommended for nonresponders to an initial standard three-dose series. We compared the safety and immunogenicity of an investigational hepatitis B surface antigen vaccine (HBsAg-1018) with a phosphorothioate oligodeoxyribonucleotide adjuvant that targets toll-like receptor-9 to a commercially available, alum-adjuvanted hepatitis B vaccine (HBsAg-Eng) in nonresponders to three previous doses (primary study) or to four to six previous doses (substudy) of HBsAg-Eng. Both vaccines were well tolerated, although HBsAg-1018 was associated with more injection-site tenderness (63.2% vs. 18.8%, p = 0.016 in the primary study and 81.8% vs. 15.4%, p = 0.003 in the substudy). No statistically significant differences in rates of seroprotection (anti-HBs concentration ≥ 10 mIU/mL) or geometric mean antibody concentrations were found in the primary study. In the substudy, a greater proportion of HBsAg-1018 recipients achieved an anti-HBs concentration ≥ 100 mIU/mL (54.5% vs. 8.3%, p = 0.027), and those responders had higher geometric mean antibody concentrations at 4 weeks (264 vs. 46.5 mIU/mL, p = 0.021) and 52 weeks (7.0 vs. 1.2 mIU/mL, p = 0.030) than HBsAg-Eng recipients. Although this study suggests that HBsAg-1018 may have improved immunogenicity in nonresponders to hepatitis B vaccine vaccination when compared with HBsAg-Eng, larger studies are required.
    MeSH term(s) Adolescent ; Adult ; Antibody Formation/immunology ; Female ; Hepatitis B/immunology ; Hepatitis B/prevention & control ; Hepatitis B Antibodies/blood ; Hepatitis B Surface Antigens/immunology ; Hepatitis B Vaccines/adverse effects ; Hepatitis B Vaccines/immunology ; Hepatitis B Vaccines/therapeutic use ; Humans ; Male ; Middle Aged ; Phosphorothioate Oligonucleotides/immunology ; Toll-Like Receptor 9/immunology ; Vaccination ; Young Adult
    Chemical Substances Hepatitis B Antibodies ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines ; Phosphorothioate Oligonucleotides ; TLR9 protein, human ; Toll-Like Receptor 9
    Language English
    Publishing date 2013-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2664176-8
    ISSN 2164-554X ; 2164-5515
    ISSN (online) 2164-554X
    ISSN 2164-5515
    DOI 10.4161/hv.24256
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6967: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Frailty Hinders Recovery From Acute Respiratory Illness in Older Adults

    Andrew, Melissa K / Lees, Caitlin / Godin, Judith / Black, Karen / McElhaney, Janet / Ambrose, Ardith / Boivin, Guy / Bowie, William R / Elsherif, May / Green, Karen / Halperin, Scott A / Hatchette, Todd / Johnstone, Jennie / Katz, Kevin / Langley, Joanne M / Leblanc, Jason / Lagace-Wiens, Philippe / Loeb, Mark / Mackinnon-Cameron, Donna /
    Mccarthy, Anne / Mcgeer, Allison / Powis, Jeff / Richardson, David / Semret, Makeda / Smith, Stephanie / Smyth, Daniel / Taylor, Geoffrey / Trottier, Sylvie / Valiquette, Louis / Webster, Duncan / Ye, Lingyun / McNeil, Shelly

    Open Forum Infect Dis

    Abstract: BACKGROUND: Influenza vaccination programs aim to prevent serious outcomes. Given that frailty may impact recovery from influenza, we examined frailty as a predictor of recovery in older adults hospitalized with acute respiratory illness. METHODS: Data ... ...

    Abstract BACKGROUND: Influenza vaccination programs aim to prevent serious outcomes. Given that frailty may impact recovery from influenza, we examined frailty as a predictor of recovery in older adults hospitalized with acute respiratory illness. METHODS: Data came from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network during the 2011/12, 2012/13, and 2013/14 influenza seasons; all patients were aged 65+. Frailty was measured using a previously validated Frailty Index (FI) of health and functional deficits; baseline frailty was categorized using published cutoffs (0-.1 non-frail, >.1-.21 pre-frail, >.21-.45 frail, >.45 most frail). Recovery was operationalized as being alive 30 days post-discharge with less than two additional health/functional deficits (<=0.06 FI increase). Logistic regression was used to examine the change in odds of recovery for every 0.1 increase in baseline FI, controlling for age, sex, season, lab-confirmed influenza status, and seasonal influenza vaccination status. RESULTS: Of 5125 hospitalized older adults, 15% were non-frail, 39% pre-frail, 40% frail, and 6% most frail. 11% died, and poor recovery was experienced by 520/4544=11% of survivors. Poor recovery was inversely associated with baseline frailty (11% non-frail, 17% pre-frail, 28% frail, 38% most frail; P < .001). Frailty was associated with lower odds of recovery in all three seasons [2011/12 (OR=0.71; 95% CI 0.60–0.85), 2012/13 (OR=0.72; 0.66–0.78), 2013/14 (OR=0.76; 0.70–0.82)] though results varied by season, influenza status, and vaccination status. In 2011/12, frailty was associated with poor recovery in unvaccinated (OR=0.46. 95% CI=0.32–0.67) but not vaccinated older patients (OR=0.83, 95% CI=0.68–1.02). CONCLUSION: Increasing frailty was consistently associated with lower odds of recovery in older adults admitted with influenza and other acute respiratory illnesses; depending on seasonal factors, vaccination may offer some buffering of this impact. Understanding frailty and functional status is important, both because frailty is predictive of poor recovery and because persistence of new health/functional deficits is an adverse outcome with important implications for patients, families and health systems. DISCLOSURES: M. K. Andrew, GSK: Grant Investigator, Research grant; Pfizer: Grant Investigator, Research grant; Sanofi-Pasteur: Grant Investigator, Research grant; J. McElhaney, GSK Vaccines: Scientific Advisor, Speaker honorarium; M. Elsherif, Canadian Institutes of Health Research: Investigator, Research grant; Public Health Agency of Canada: Investigator, Research grant; GSK: Investigator, Research grant; S. A. Halperin, GSK: Scientific Advisor, Consulting fee; GSK: Grant Investigator, Research grant; T. Hatchette, GSK: Grant Investigator, Grant recipient; Pfizer: Grant Investigator, Grant recipient; Abbvie: Speaker for a talk on biologics and risk of TB reactivation, Speaker honorarium; J. M. Langley, GSK: Investigator, Research grant; Canadian Institutes of Health Research: Investigator, Research grant; A. Mcgeer, Hoffman La Roche: Investigator, Research grant; GSK: Investigator, Research grant; sanofi pasteur: Investigator, Research grant; J. Powis, Merck: Grant Investigator, Research grant; GSK: Grant Investigator, Research grant; Roche: Grant Investigator, Research grant; Synthetic Biologicals: Investigator, Research grant; M. Semret, GSK: Investigator, Research grant; Pfizer: Investigator, Research grant; S. Trottier, Canadian Institutes of Health Research: Investigator, Research grant; L. Valiquette, GSK: Investigator, Research grant; S. McNeil, GSK: Contract Clinical Trials and Grant Investigator, Research grant; Merck: Contract Clinical Trials and Speaker’s Bureau, Speaker honorarium; Novartis: Contract Clinical Trials, No personal renumeration; sanofi pasteur: Contract Clinical Trials, No personal renumeration
    Keywords covid19
    Publisher PMC
    Document type Article ; Online
    DOI 10.1093/ofid/ofx163.1500
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top